Rodriguez Pedro C, Gonzalez Ileana, Gonzalez Adys, Avellanet Janet, Lopez Armando, Perez Rolando, Lage Agustin, Montero Enrique
Experimental Immunotherapy Department, Center of Molecular Immunology, 216 Street & 15, Playa, P.O. Box 16040, Havana 11600, Cuba.
Vaccine. 2008 Aug 26;26(36):4647-54. doi: 10.1016/j.vaccine.2008.07.003. Epub 2008 Jul 18.
Epidermal Growth Factor chemically conjugated to P64k carrier protein from Neisseria meningitidis emulsified in Montanide ISA 51 adjuvant is a cancer vaccine under clinical evaluation. We explored the influence of priming and boosting variables on the antibody response in mice. An apparently low dose fractionated in multiple anatomical sites at priming accelerated the induction and enhanced the maximal antibody response, with a long-lasting effect. Moreover, shortening the boosting time reduces the antibody persistence. Repeatedly boosting shift subjects to good antibody-responders, maintaining the epitope immunodominance. We conclude that optimizing immunopharmacological determinants contribute to an earlier, stronger and prolonged anti-EGF antibody persistence.
与来自脑膜炎奈瑟菌的P64k载体蛋白化学偶联的表皮生长因子，乳化于Montanide ISA 51佐剂中，是一种正在进行临床评估的癌症疫苗。我们探讨了初次免疫和加强免疫变量对小鼠抗体反应的影响。初次免疫时在多个解剖部位给予明显低剂量的疫苗，可加速诱导并增强最大抗体反应，且具有持久效应。此外，缩短加强免疫时间会降低抗体持久性。反复加强免疫可使受试者转变为良好的抗体应答者，维持表位免疫显性。我们得出结论，优化免疫药理学决定因素有助于更早、更强且更持久地产生抗表皮生长因子抗体。
